Clinical trials · New York
Cardiomyopathies clinical trials in New York
We’re tracking 30 recruiting cardiomyopathies studies with a site in New York — including Phase 1, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT06610019Recruiting
Heart imaging study using MRI
This study uses heart MRI scans to learn more about cardiovascular health in adults. If you are 18 or older and have been referred for a heart MRI at Montefiore, you may be able to join.
The Bronx, New YorkAges 18 years+ - NCT07052903RecruitingPhase 3
RNA therapy for ATTR amyloidosis with heart involvement
This trial tests an experimental RNA therapy (nucresiran) for people with transthyretin amyloidosis that causes heart problems (cardiomyopathy). It aims to lower the abnormal protein buildup to help heart function.
Manhasset, New YorkAges 18–85 - NCT05180773RecruitingPhase 4
Bromocriptine for new postpartum heart weakness
This trial studies whether bromocriptine improves health outcomes in people recently diagnosed with peripartum cardiomyopathy (a weakened heart during late pregnancy or soon after delivery). You may be asked about timing after childbirth, heart strength tests, and whether you plan to keep breastfeeding.
New York, New YorkAges 18 years+ - NCT07210723RecruitingPhase 2/Phase 3
Study of danicamtiv for genetic and familial dilated cardiomyopathy
This trial tests if danicamtiv can improve heart function in people with dilated cardiomyopathy caused by certain genetic changes. It may help those who have stable symptoms but still need more treatment options.
New York, New YorkAges 18 years+ - NCT06412666RecruitingPhase 2/Phase 3
Aficamten for teens with obstructive hypertrophic cardiomyopathy
This trial tests a new medicine called aficamten for teenagers with a heart condition that makes the heart muscle too thick and blocks blood flow. The medicine may help make the heart pump more easily and improve symptoms like shortness of breath or chest pain.
New York, New YorkAges 12–17 - NCT06563895RecruitingPhase 3
Testing acoramidis to prevent ATTR amyloidosis in gene carriers
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
New York, New YorkAges 18–75 - NCT03663348Recruiting
Patient registry for Takotsubo (stress) heart syndrome
This study is a patient registry that collects information from people diagnosed with Takotsubo syndrome, also known as a stress-related heart condition. It may help researchers learn more about who is affected and how the condition behaves over time.
New York, New YorkAges 18–110 - NCT05112237Recruiting
Study of children’s heart disease caused by MYBPC3 gene changes
This is an observational study that follows children under 18 with cardiomyopathy caused by certain MYBPC3 gene mutations. It aims to better understand how the disease changes over time, which may help future treatments be better targeted.
Lake Success, New YorkAges birth–18 years - NCT05302271RecruitingPhase 1
Testing gene therapy for Friedreich’s ataxia heart disease
This Phase 1 trial tests an AAV gene therapy that aims to improve heart problems caused by Friedreich’s ataxia. You may be eligible if you have genetically confirmed Friedreich’s ataxia with measurable heart weakening but still enough heart function to safely receive treatment.
New York, New YorkAges 12–50 - NCT05489705Recruiting
Real-world registry for mavacamten and other obstructive HCM treatments
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
Cooperstown, New YorkAges 18 years+ - NCT06128629RecruitingPhase 3
A study of NTLA-2001 for transthyretin amyloidosis with heart problems
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
New York, New YorkAges 18–90 - NCT06311708Recruiting
PKP2-related heart condition natural history study
This study looks at how plakophilin 2 (PKP2)-related arrhythmogenic right ventricular cardiomyopathy (ARVC) progresses over time. You'll give blood samples to check for antibodies to a virus used in gene therapy, and help doctors understand the disease better.
New York, New YorkAges 14–65 - NCT07023614RecruitingPhase 2
Study of Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy
This trial tests an investigational drug (ninerafaxstat) for people with a specific type of thickened heart muscle called non-obstructive hypertrophic cardiomyopathy. The goal is to see if the drug can improve symptoms and exercise ability.
New York, New YorkAges 18 years+ - NCT06679946Enrolling by invitationPhase 3
Study of Vutrisiran for heart condition from TTR amyloidosis
This study tests a drug called vutrisiran for people with a condition called transthyretin amyloidosis that affects the heart. It is for patients who have already been in certain earlier studies of patisiran or vutrisiran.
New York, New YorkAges 18 years+ - NCT05667493Enrolling by invitationPhase 3
Long-term safety follow-up for eplontersen in ATTR heart disease
This is a long-term study to check the safety of eplontersen over time in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). It is mainly for people who already took the study medication before, or who joined an earlier related study and are doing well.
New York, New YorkAges 18 years+ - NCT06080074RecruitingPhase 2
Emergency heart-lung machine study for children with severe heart failure
This study tests a specific heart-lung machine called Cardiohelp to help children with severe heart failure. It looks at how well the machine works and whether a blood thinner (either heparin or bivalirudin) is safer and more effective.
New York, New YorkAges birth–16 years - NCT07207811RecruitingPhase 3
Study of coramitug for heart failure from ATTR amyloidosis
This study tests an investigational medicine called coramitug in people with heart failure caused by ATTR amyloidosis, a condition where abnormal protein builds up in the heart. The goal is to see if it can slow or improve heart function.
Manhasset, New YorkAges 18 years+ - NCT05034432RecruitingPhase 4
Test treatment for dangerous heart rhythm episodes in LVAD patients
This trial studies a procedure to fix abnormal heart rhythms (ventricular tachycardia or ventricular fibrillation) in people who have an LVAD and a defibrillator (ICD) or an alternative device. It may help prevent future dangerous rhythm episodes after LVAD treatment.
New York, New YorkAges 18 years+ - NCT05489549Recruiting
Study of heart amyloid risk in people with TTR gene variants
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
New York, New YorkAges 30–80 - NCT05650658Recruiting
Compare two heart pacing options in people with weak heart function
This trial compares two types of “left-side” heart pacing to see which one works better in people with weak heart pumping. It may help guide the best pacing choice for improving heart function and symptoms.
New York, New YorkAges 18 years+ - NCT05977049Recruiting
Support program for adults with Takotsubo syndrome
This trial studies a psychosocial (emotional and coping) support approach for adults with Takotsubo syndrome. It may help patients deal with stress, anxiety, or adjustment related to the condition.
New York, New YorkAges 18 years+ - NCT06034405Recruiting
Checking spine tissue for heart amyloidosis signs
This trial is looking at leftover tissue from past spine surgeries to see if it contains signs of a heart condition called TTR amyloidosis. It may help find people who have this condition early.
New York, New YorkAges 50 years+ - NCT06228924RecruitingPhase 1
Gene therapy for ARVC with PKP2 mutation
This trial tests a new gene therapy called TN-401 for people with ARVC caused by a specific PKP2 gene mutation. The goal is to see if the treatment is safe and can help reduce dangerous heart rhythms.
New York, New YorkAges 18–65 - NCT06699056Recruiting
AI heart monitor study for ejection fraction
This study uses an AI-powered wearable monitor to check how well your heart pumps blood (ejection fraction) from a simple EKG recording. It may help doctors quickly assess heart function without extra tests.
New York, New YorkAges 18 years+
Cardiomyopathies trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting cardiomyopathies studies listed above.
- Columbia University Irving Medical Center · 12 studies
- NYU Langone Health · 6 studies
- Weill Cornell Medicine · 5 studies
- Mount Sinai Hospital · 4 studies
- Clinical Trial Site · 2 studies
- Laurelton Heart Specialist PC · 2 studies
- Montefiore Medical Center · 2 studies
- Mount Sinai Health System · 2 studies
What taking part in a cardiomyopathies study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cardiomyopathies trials in other states
Common questions
- Are there cardiomyopathies clinical trials in New York?
- Yes. We're currently tracking 30 recruiting cardiomyopathies studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cardiomyopathies study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cardiomyopathies trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cardiomyopathies studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.